SCHEMBL3473362

SCHEMBL3473362

CC(C)(O)c1cc(-c2ccc(-c3cccc4[nH]ccc34)cc2)n(-c2ccccc2Cl)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 4/20 0.48
NR1H2 P55055 4/20 0.48
NR1H3 Q13133 4/20 0.48
PIK3CD O00329 3/20 0.39
CHRNA7 P36544 2/20 0.38
KCNH2 Q12809 2/20 0.38
NR3C2 P08235 1/20 0.37
FTO Q9C0B1 1/20 0.37
PIK3CB P42338 2/20 0.36
MAPK14 Q16539 1/20 0.36
PIP4K2A P48426 1/20 0.36
PIP4K2B P78356 1/20 0.36
PIP4K2C Q8TBX8 1/20 0.36
CSNK2B P67870 1/20 0.36
CSNK2A1 P68400 1/20 0.36
PIK3CG P48736 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
FABP3 P05413 1/20 0.36
FABP4 P15090 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3475217 0.86 RXRA (0.59) RXRANR1H2NR1H3FTOMAPK14
SCHEMBL3475637 0.82 RXRA (0.48) RXRANR1H2NR1H3PIK3CDNR3C2
SCHEMBL3472972 0.82 RXRA (0.48) RXRANR1H2NR1H3CHRNA7KCNH2
SCHEMBL3471076 0.76 RXRA (0.57) RXRANR1H2NR1H3NR3C2
SCHEMBL3472324 0.76 RXRA (0.57) RXRANR1H2NR1H3KCNH2NR3C2
SCHEMBL3471188 0.75 RXRA (0.56) RXRANR1H2NR1H3NR3C2FABP3
SCHEMBL3471370 0.75 RXRA (0.62) RXRANR1H2NR1H3NR3C2MAPT
SCHEMBL3471745 0.75 RXRA (0.62) RXRANR1H2NR1H3NR3C2MAPK14
SCHEMBL3472064 0.75 RXRA (0.51) RXRANR1H2NR1H3NR3C2PDPK1
SCHEMBL3470712 0.74 RXRA (0.67) RXRANR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
EP-1910307-A1 PYRAZOLE BASED LXR MODULATORS Exelixis, Inc. (US) 2008-04-16 EP disclosed
WO-2007002559-A1 PYRAZOLE BASED LXR MODULATORS EXELIXIS, INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 RXRA 18/4885NR1H2 1/4885NR1H3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.